Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to the development of biopharmaceuticals and other blue ocean bio-products. GBB aims to ultimately solve numerous pain-points found in the biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since establishment, the company has obtained massive drug development data from its 3100 m2 international level CMC facility. Prior, GBB has successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created an intelligent centralized database, where deep learning is being performed to create a next generation AI-enabled bioprocessing ecosystem. Combining cutting-edge AI technology and years of experience in drug research and development, GBB has successfully developed a series of intelligent bioprocessing platforms since 2019. Currently, Klone4.0TM (AI-enabled cell line development platform), AlfaStaXTM (AI-enabled cell line stability prediction platform) and AlfaMedX® (AI-enabled culture media development platform) are commercially available.